News

February 26, 2014
Eisai began a Phase III trial to compare the efficacy, safety and tolerability of eribulin mesylate to standard weekly paclitaxel as a first- or second- line treatment for HER2-negative locally recurrent or metastatic breast cancer. Recruitment is currently active for this multicenter study,...
February 24, 2014
Eli Lilly's experimental drug dulaglutide was as good at controlling type 2 diabetes as the leading treatment in a clinical trial, providing Lilly with a potential marketing advantage as it seeks to gain approval of the medicine, reports Bloomberg. Once-a-week dulaglutide was shown to be non-...
February 23, 2014
Bayer said it has clinched a $2.9-billion deal to take over Norwegian cancer drugmaker Algeta after being tendered 92.17% of the shares in a cash offer, the company said. Bayer extended the acceptance deadline by two days to Feb. 26, and said it expected the deal to close in the first quarter....
February 20, 2014
Janssen initiated a global, multicenter Phase III study evaluating whether Invokana (canagliflozin) can slow the progression of diabetic nephropathy, a form of renal impairment that is the most common cause of end-stage renal disease worldwide. The randomized, double-blind, placebo-controlled trial...
February 19, 2014
The EMA's Committee for Medicinal Products for Human Use recommended marketing authorization for Anoro, a drug co-developed by GSK and Theravance for the treatment of COPD patients. The drug still needs to be given final approval by the European Commission before it can be sold in Europe. That...

Pages